Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | OXER1 | Q8TDS5 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | PPARD | Q03181 | 4/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005144 | 0.81 | ACLY (0.52) | ACLYOXER1PPARGPPARAPPARD | |
| SCHEMBL22004131 | 0.78 | CCR2 (0.51) | ACLYCCR2PHGDH | |
| SCHEMBL22003794 | 0.72 | MAPT (0.46) | ACLYCCR2PHGDH | |
| SCHEMBL22004112 | 0.71 | ACLY (0.57) | ACLYCCR2PHGDH | |
| SCHEMBL8689671 | 0.71 | NOD2 (0.47) | CCR2 | |
| SCHEMBL1576398 | 0.71 | PTGDR2 (0.51) | ACLYKMOCCR2PHGDH | |
| SCHEMBL19360574 | 0.70 | RORC (0.65) | PPARGRORC | |
| SCHEMBL9239997 | 0.69 | TDP1 (0.42) | OXER1CCR2 | |
| SCHEMBL22003798 | 0.69 | ACLY (0.44) | ACLYPHGDH | |
| SCHEMBL22021595 | 0.69 | ACLY (0.45) | ACLYPPARGPPARAPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885OXER1 4240/4885PPARG 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.